South Africa has resumed its phase I rollout of the Johnson and Johnson COVID-19 vaccine. An ongoing study on healthcare workers was halted for two weeks after dangerous clotting was found in six U.S. patients. Close to 300,000 medical workers have received the jab with no reports of clotting and the program was allowed to resume.
